Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Hold Rating from Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reissued by Needham & Company LLC in a research note issued on Tuesday, Benzinga reports.

Separately, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a report on Monday, April 15th.

Lexicon Pharmaceuticals Stock Up 3.6 %

Shares of NASDAQ LXRX opened at $1.71 on Tuesday. The stock has a market capitalization of $421.07 million, a P/E ratio of -2.14 and a beta of 1.27. The company has a 50-day moving average price of $2.34 and a 200-day moving average price of $1.72. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.79. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. On average, equities research analysts forecast that Lexicon Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL raised its position in Lexicon Pharmaceuticals by 22.2% in the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after acquiring an additional 4,440,300 shares during the period. Swiss National Bank raised its position in Lexicon Pharmaceuticals by 4.4% in the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 10,300 shares during the period. SG Americas Securities LLC bought a new stake in Lexicon Pharmaceuticals in the third quarter worth about $64,000. KWB Wealth bought a new stake in Lexicon Pharmaceuticals in the fourth quarter worth about $62,000. Finally, Commonwealth Equity Services LLC raised its position in Lexicon Pharmaceuticals by 160.9% in the third quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 24,400 shares during the period. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.